ImmunoGen Announces Dr. Charles Morris as New Chief Development Officer

ImmunoGen

, a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the appointment of Charles Morris, MB, ChB, MRCP as Executive Vice President and Chief Development Officer, effective today. Dr. Morris will be responsible for leading all aspects of product development, including regulatory, at ImmunoGen. He reports to Daniel Junius, President and Chief Executive Officer. “Charlie has extensive experience leading the strategic development and registration of novel oncology compounds – expertise essential to ImmunoGen with our advancing and expanding product pipeline,” commented Mr. Junius. “We now have three wholly owned clinical-stage compounds,